Visiox Pharma Appoints Industry Veteran Vicente Anido Jr., Ph.D., as Strategic Advisor

Vicente Anido Jr.Ph.D., joins as strategic advisor to advance two products to market and inform growth strategy

TARRYTOWN, NY, June 15, 2022 /PRNewswire/ — Visiox Pharma, LLC., a privately funded biopharmaceutical company focused on the development and commercialization of ophthalmic therapeutic candidates to treat prevalent diseases requiring new treatment options, announced today that it has appointed Vicente Anido Jr.doctorate as a strategic advisor.

“We are thrilled to have Vince join the team,” said ryan bleeks, CEO of Visiox. “His experience will help us further strengthen our position as we accelerate towards commercialization.”

“It’s an exciting time in eye care to establish a new company that follows in the footsteps of a proven business platform,” commented Vicente Anido. “I look forward to helping bring two new drugs to market in the largest eye care markets within a year, while evaluating other late-stage products to expand the Visiox pipeline.”

Vicente Anido Jr., Ph.D. joins as a strategic advisor, bringing over 3 decades of ophthalmology experience in building profitable organizations, and will be key in advising Visiox on the way forward. Its proven success in bringing products to market and raising capital will further strengthen our position as a leading player in the field of ophthalmology. Vince served as CEO at Aerie Pharmaceuticals for over 8 years, following a decade at ISTA Pharmaceuticals as CEO. ISTA Pharmaceuticals was sold to Bausch & Lomb for $500 million in 2012.

About Visiox

Visiox is a privately funded biopharmaceutical company focused on the development and commercialization of ophthalmic therapeutic candidates to treat widespread diseases requiring novel treatment options. Every day is an opportunity for us to disrupt and revolutionize today’s market to maximize patient and physician satisfaction. As an agile business partner, we will achieve this through a high level of collaboration with all eyecare professionals.

Visiox plans to submit two New Drug Applications to the US FDA later this year in the glaucoma and cataract surgery markets. Our lead candidate, PDP-716, is a novel once-daily formulation of brimonidine utilizing our patented TearAct™ delivery technology, which provides slow, consistent, and sustained release for all-day IOP control. . Glaucoma affects 53 million people worldwide and is expected to reach 80 million by 20401. SDN-037 is a twice-daily topical corticosteroid difluprednate using our patented TJM™ (Tight Junction Modulation) micellar platform. The new technology offers powerful post-surgical inflammation control in a clear solution allowing for convenient dosing with a proven active ingredient. Cataract extraction is the most performed eye surgery in the United States. It accounts for 70% of all eye surgeries. 50 million people are expected to have cataracts in the United States by 20502. For more information, please visit Visiox Pharma Where LinkedIn.

1. Tham YC. Global prevalence of glaucoma and projections of glaucoma burden to 2040. Ophthalmology. 2014 Nov;121(11):2081-90
2. Eye Surgery Procedures: Market Scope, 2019

Corporate contact details

Ryan S. Bleeks
Chief executive officer
[email protected]

Show original content to download multimedia:

SOURCE Visiox Pharma LLC

Comments are closed.